Resilience is a new biopharmaceutical company founded in 2020, striving to transform the way that drugs and therapies are manufactured through creating a first-of-its-kind ecosystem for advanced biopharmaceutical manufacturing.
Identifying problems faced in the biopharmaceutical manufacturing process as one of the most significant barriers in bringing novel treatments to market, the company’s founders created Resilience to reimagine this process and enable their partners to focus on the discoveries that improve patients’ lives.
The Resilience platform includes standardized processes, innovative technologies, regulatory capabilities, quality assurance and smart informatics combined with customized manufacturing and development capabilities aiming to serve the needs of biopharmaceutical companies at all stages of the drug development process – from pre-clinical development to commercial supply. These new manufacturing technologies include cell and gene therapies, viral vectors, vaccines and proteins.
In mid-2021, the JIMCO Life Sciences Fund, the dedicated biotech innovation and venture fund of JIMCO, the Jameel Family’s global investment arm, participated in Reslience’s Series C funding round.
Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need. Bringing together leading minds in science and engineering with the most advanced technologies to build a resilient industry future.
Explore other partners
